A 62-year-old man with Parkinson's disease is being counselled about dopaminergic agents. Which of the following statements about antiparkinsonian drugs is NOT true?

Explanation

## Analysis of Antiparkinsonian Drug Pharmacology ### Correct Statements (Options 0, 2, 3) **Option 0 — Levodopa Transport:** **Key Point:** Levodopa (L-DOPA) is an amino acid that crosses the blood-brain barrier via LAT-1, a saturable transporter. Dopamine itself is a catecholamine and is highly polar — it cannot cross the BBB, which is why levodopa (its precursor) is used instead. Carbidopa (a peripheral decarboxylase inhibitor) is co-administered to prevent premature conversion in the periphery. **Option 2 — Selegiline:** **Key Point:** Selegiline irreversibly inhibits monoamine oxidase-B (MAO-B), the enzyme that metabolizes dopamine in the brain. It can be used as monotherapy in early-stage PD and delays the need for levodopa by ~9–12 months. **Option 3 — Entacapone:** **Key Point:** Entacapone inhibits catechol-O-methyltransferase (COMT), a peripheral enzyme that inactivates levodopa. By blocking this pathway, it prolongs levodopa half-life and reduces "off" periods in fluctuating PD. ### Incorrect Statement (Option 1 — The Answer) **Warning:** This is a common misconception in exam halls. **High-Yield:** Bromocriptine is a **D2-selective dopamine agonist**, but it does **NOT** cause fewer dyskinesias than levodopa. In fact: - Dopamine agonists (bromocriptine, pramipexole, ropinirole) cause **similar or even higher rates of motor complications** (dyskinesias, on-off fluctuations) when used as monotherapy. - The advantage of dopamine agonists is **lower dyskinesia risk when used as adjuncts to levodopa** in early PD, not when used alone. - Levodopa monotherapy in early PD actually has the **lowest dyskinesia incidence** in the first 5 years. **Clinical Pearl:** The choice between levodopa and dopamine agonists in early PD is based on age and motor complications risk, not dyskinesia prevention — younger patients are often started on agonists to delay levodopa exposure, but this does not reduce dyskinesia risk. ### Summary Table | Drug Class | Mechanism | Key Advantage | Key Limitation | | --- | --- | --- | --- | | Levodopa | Dopamine precursor (crosses BBB) | Most potent, fastest onset | Highest dyskinesia risk with prolonged use | | Dopamine agonists (bromocriptine) | D1/D2 receptor agonism | Delays levodopa, lower early dyskinesia as adjunct | Similar dyskinesia when monotherapy | | Selegiline | MAO-B inhibitor | Monotherapy option, delays levodopa need | Modest effect, amphetamine metabolites | | Entacapone | COMT inhibitor | Extends levodopa half-life | Adjunct only, diarrhea, orange urine |